BCMA72-80

CAS No. 2293841-58-2

BCMA72-80( —— )

Catalog No. M30504 CAS No. 2293841-58-2

BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with a strong affinity to HLA-A2. It is used to used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    BCMA72-80
  • Note
    Research use only, not for human use.
  • Brief Description
    BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with a strong affinity to HLA-A2. It is used to used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.
  • Description
    BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with a strong affinity to HLA-A2. It is used to used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2293841-58-2
  • Formula Weight
    1196.55
  • Molecular Formula
    C59H97N13O11S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:Tyr-Leu-Met-Phe-Leu-Leu-Arg-Lys-Ile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Bae J, et al. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 Mar 12.
molnova catalog
related products
  • 680C91

    680C91 is a potent and selective inhibitor of TDO, and its Ki is 51 nM.

  • AD 01

    FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.

  • A2ti-2

    A2ti-2 is a low affinity and selective inhibitor of the membrane-bound protein A2/S100A10 heterotetramer (A2t) (IC50 : 230 μM).